

# PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
Name	Execution Date
GeneSense Technologies Inc.	06/01/2009
<b>RECEIVING PARTY DATA</b>	
Name:	Lorus Therapeutics Inc.
Street Address:	2 Meridian Road
City:	Toronto, Ontario
State/Country:	CANADA
Postal Code:	M9W 4Z7
<b>PROPERTY NUMBERS Total: 1</b>	
Property Type	Number
Application Number:	11915257
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(513)651-6981
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	5136516131
Email:	pspradlin@fbtlaw.com
Correspondent Name:	Steven J. Goldstein
Address Line 1:	201 East Fifth Street
Address Line 2:	2200 PNC Center
Address Line 4:	Cincinnati, OHIO 45202
ATTORNEY DOCKET NUMBER:	0113866/0555186
NAME OF SUBMITTER:	Steven J. Goldstein
<p>Total Attachments: 6</p> <p>source=ASSGNMT#page1.tif</p> <p>source=ASSGNMT#page2.tif</p> <p>source=ASSGNMT#page3.tif</p>	

OP \$40.00 11915257

**500880078**

**PATENT**  
**REEL: 022794 FRAME: 0635**

source=ASSGNMT#page4.tif  
source=ASSGNMT#page5.tif  
source=ASSGNMT#page6.tif

## ASSIGNMENT OF INVENTION

This Assignment is effective as of May 31, 2009.

In consideration of One (\$1.00) Dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we,

**GENESENSE TECHNOLOGIES INC.** (hereinafter "the Assignor"), having a place of business at **2 Meridian Road, Toronto, Ontario M9W 4Z7, Canada,**

have agreed to sell, assign and transfer, and do hereby sell, assign and transfer effective as of May 31, 2009 to

**LORUS THERAPEUTICS INC.** (hereinafter "the Assignee"), having a place of business at **2 Meridian Road, Toronto, Ontario M9W 4Z7, Canada,**

all our right, title and interest throughout the world in and to (1) the inventions relating to and described and/or claimed in the patent applications and patents listed in Schedule A; (2) all improvements, including but not limited to modifications, additions, substitutions, derivatives, and deletions to said invention(s); (3) the patent applications and patents listed in Schedule A and national phase applications thereof; (4) all other applications for Letters Patent in any country throughout the world for said invention(s) and improvements, including but not limited to all divisional, continuation, continuation-in-part, renewal, reissue, and substitute applications; (5) any Letters Patent which may issue from any of said applications as exemplified in (3) and (4) above in any country throughout the world; (6) all Convention or Treaty rights derived from any of said applications, including without limitation, all rights of priority throughout the world in and to said applications; and (7) the full and complete right to file applications for Letters Patent in the name of the Assignee, or in our name at the Assignee's election, on said invention(s) and improvements in all countries throughout the world.

For said consideration, the Assignor agrees, upon the request and at the expense of the Assignee, its successors and assigns, to execute any and all divisional, continuation, continuation-in-part, reissue and substitute applications for said invention(s) and improvements, and acknowledge and agree that all rights therein shall vest in the Assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by said Assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made.


In addition, the Assignor will, at the request of the Assignee, execute any and all documents required by the Assignee to fully and properly vest the aforementioned rights in the Assignee.

The undersigned hereby grants to the firm of **MBM Intellectual Property Law LLP** whose full post office address is P.O. Box 809, Station B, Ottawa, Ontario, Canada, K1P 5P9,

the power to insert on this assignment any further information and/or correct any clerical error in the information pertaining to the referenced applications and patents, which may be necessary or desirable in order to comply with the patent legislation for recordation of this document.

**FOR THE ASSIGNOR:**

SIGNED at Toronto, Ontario, Canada, this 1 day of June, 2009.

  
\_\_\_\_\_


(Signature)

Name: Aiping Young

Title: President & CEO

**GENESENSE TECHNOLOGIES INC.**

I was personally present and did see Aiping Young duly sign and execute the above assignment.

  
\_\_\_\_\_

(Signature of witness)

Elizabeth Williams

(Name of witness)

**FOR THE ASSIGNEE:**

SIGNED at Toronto, Ontario, Canada, this 1 day of June, 2009.

  
\_\_\_\_\_


(Signature)

Name: Aiping Young

Title: President & CEO

**LORUS THERAPEUTICS INC.**

I was personally present and did see Aiping Young duly sign and execute the above assignment.

  
\_\_\_\_\_

(Signature of witness)

Elizabeth Williams

(Name of witness)

**Schedule A****Immunomodulating Compositions from Bile  
(Virulizin)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>	<b>Patent #</b>
AUSTRALIA	9/9/1994	97242/98	732816
CANADA	9/9/1994	2,171,281	2,171,281
CHINA	9/9/1994	94194002.0	94194002.0
EUROPE (Germany, Spain, France, Italy, Great Britain)	9/9/1994	94926737.1	717631
HONG KONG	9/9/1994	98107139.0	HK1007922
JAPAN	9/9/1994	508370/95	
SOUTH KOREA	9/9/1994	96-701198	260110
MEXICO	9/9/1994	9406945	212,218
NEW ZEALAND	9/9/1994	273,258	273258
UNITED STATES	9/9/1994	08/612,921	6,280,774
UNITED STATES	1/7/2000	09/479,835	6,551,623
UNITED STATES	12/13/2006	11/637,921	

**IMMUNOMODULATING COMPOSITIONS FROM BILE FOR THE TREATMENT OF  
IMMUNE SYSTEM DISORDERS  
(Virulizin)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>	<b>Patent #</b>
AUSTRALIA	3/13/1996	48739/96	711294
CANADA	3/13/1996	2,215,339	2,215,339
BRAZIL	3/13/1996	PI9607967	
JAPAN	3/13/1996	8(1996)-527137	
MEXICO	3/13/1996	977111	254072
SINGAPORE	3/13/1996	9705689-9	50147

**IMMUNOMODULATING COMPOSITIONS FOR TREATMENT OF IMMUNE SYSTEM  
DISORDERS  
(Virulizin)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>	<b>Patent #</b>
UNITED STATES	1/17/2001	09/764,010	6,596,319

**IMMUNOMODULATING COMPOSITIONS FOR THE TREATMENT OF VIRAL DISORDERS  
(Virulizin)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>	<b>Patent #</b>
SOUTH AFRICA	7/13/1998	986,224	986,224

**COMBINATION PREPARATION OF A BIOLOGICAL RESPONSE MODIFIER AND AN ANTICANCER AGENT AND USES THEREOF**

(Virulizin in combination with chemotherapy)

Country	Filed	Serial #
CANADA	11/8/2001	2,428,145
EUROPE	11/8/2001	1983364.9
HONG KONG	11/8/2001	4100981.7
UNITED STATES	4/2/2008	12/061,274

**2,4,5-TRISUBSTITUTED IMIDAZOLES AND THEIR USE AS ANTI-MICROBIAL AGENTS**  
(ML-220)

Country	Filed	Serial #
AUSTRALIA	8/19/2003	2003257329
BRAZIL	8/19/2003	PI0313763-5
CANADA	8/19/2003	2,496,241
CHINA	8/19/2003	3824355.5
EUROPE	8/19/2003	3787546.5
HONG KONG	10/24/2005	5109435.9
JAPAN	8/19/2003	2004-528206
MEXICO	8/19/2003	2005/002040
UNITED STATES	3/19/2003	10/525,690

**ARYL IMIDAZOLES AND THEIR USE AS ANTICANCER AGENTS**  
(ML-133)

Country	Filed	Serial #
AUSTRALIA	11/15/2004	2004289539
CANADA	11/15/2004	2,545,942
EUROPE	11/15/2004	4799154.2
HONG KONG	11/15/2004	07102016.9
JAPAN	11/15/2004	2006-539065
UNITED STATES	11/15/2004	10/579,149

**USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER**

Country	Filed	Serial #
CANADA	3/8/2006	2,599,754
EUROPE	3/8/2006	06705265.4
UNITED STATES	3/8/2006	11/817,914

**2-INDOLYL IMIDAZO[4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER**

Country	Filed	Serial #
Australia	5/26/2006	2006250809
Canada	5/25/2006	2,611,032
China	5/25/2006	200680023377.2
Europe	5/25/2006	06756007.8

Japan	5/25/2006	2008-513005
United States	5/25/2006	11/915,257

**USE OF 2-INDOLYL IMIDAZO[4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION AND ALLERGIES**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
United States	12/1/2008	61/118,669

**2-INDOLYL IMIDAZO [4,5-D] PHENANTHROLINE DERIVATIVES AND USES THEREOF IN COMBINATION WITH CHEMOTHERAPEUTICS IN THE TREATMENT OF CANCER**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
United States	12/1/2008	61/118,671

**2-INDOLYL IMIDAZO[4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT OR PREVENT ANGIOGENESIS**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
United States	3/12/2009	61/159,705

CANADA


)

Province of Ontario

)

)

On this 1st day of JUNE, 2009, before me, GERALD W.  
MACLEWIE, a Notary Public in and for the Province of Ontario,  
personally appeared Aiping Young, personally known to me or proven on the basis of  
satisfactory evidence to be the person whose name is subscribed to the within instrument,  
and acknowledged to me that she executed the same in her capacity, and that by her  
signature on the instrument the person, or the entity upon behalf of which the person  
acted, executed the instrument.



A NOTARY PUBLIC IN AND FOR THE  
PROVINCE OF ONTARIO